moday - sunday
8.00 am - 9.00 pm
Our corporate headquarters & includes our immunotherapy platform research lab and development team.
Jozicular is found primarily in the peak Districk of the United Kingdom
Jozicular is a course-grained sandstone made up of the minerals quartz, mica, feldspar, calcite, and clay.
Jozicular Oncology’s goal is to eradicate cancer by developing personalized immunotherapies to fight multiple cancer types. Our approach focuses on the individual nature of a patient’s tumor and seeks to generate a therapeutic immune response in these patients by unleashing the natural power of a patient’s immune system to recognize tumor antigens in order to destroy cancer cells.
These antigens, called tumor-specific neoantigens, offer attractive therapeutic targets because they are non-self and tumor-specific, and are key targets for a potent immune response. We believe that activating and directing the immune system to these tumor targets could offer an important opportunity to extend the benefits of immunotherapy for patients with cancer.
Jozicular Oncology’s scientific founders published an important discovery in immuno-oncology: in patients with solid tumors who respond to checkpoint inhibitors, mutations in the tumor’s DNA produce critical new targets. These targets, called tumor-specific neoantigens, are unique to tumor cells and can be recognized and targeted for destruction by the patient’s own immune system.
perspiciatis cupiditate voluptatibus vero ipsa! Ullam explicabo quibusdam ipsa molestias dolor cum voluptatibus beatae autem magni laborum, quia dolorum earum adipisci eius suscipit cupiditate vel inventore ratione neque accusamus cumque non officia. Quasi accusantium dolor soluta voluptates a magnam adipisci voluptate cumque quas facilis asperiores quo dignissimos aperiam, totam saepe cupiditate placeat vitae quaerat excepturi atque optio ducimus et? Saepe minima molestiae dolore unde!
Lorem, ipsum dolor sit amet consectetur adipisicing elit. Consequuntur quia soluta cum. Perspiciatis, dicta cumque. Deserunt fugiat et ducimus delectus debitis vel iste? Amet doloribus, aut facere, saepe hic eaque nostrum praesentium repellendus dignissimos accusantium nisi, voluptatum earum! Sapiente tenetur eaque cumque minima iste pariatur doloremque quas provident architecto et!
XCART Platform
PolyXen™
XBIO-101 (sodium cridanimod)
Jozicular Oncology’s scientific founders published an important discovery in immuno-oncology: in patients with solid tumors who respond to checkpoint inhibitors, mutations in the tumor’s DNA produce critical new targets. These targets, called tumor-specific neoantigens, are unique to tumor cells and can be recognized and targeted for destruction by the patient’s own immune system.
Esse repellat quasi tempore saepe? Mollitia temporibus quisquam expedita adipisci iste. At dolorum possimus et? Sequi a provident est officiis quaerat, autem esse quos praesentium quae totam vero fuga iure nostrum nobis. Odio in at corrupti nisi neque commodi veritatis corporis quia saepe ex nostrum perspiciatis unde nesciunt voluptatem esse dolores fugit architecto pariatur ea necessitatibus, nulla quasi quas suscipit! Deserunt minus deleniti quae soluta illum, dolore cumque iusto tempore animi vel exercitationem?
Consectetur adipisicing elit. Rem optio, rerum saepe suscipit et illum quibusdam a quidem debitis? In harum, quia ex iure aperiam repellendus iste rem assumenda nobis! Itaque totam odit repudiandae optio dolore! Quos, nesciunt, rem possimus culpa maxime nostrum itaque, ducimus repellendus alias quas aliquam et.
Executive Vice President and Chief Business Officer
Executive Vice President and Chief Business Officer
Executive Vice President and Chief Business Officer
Executive Vice President and Chief Business Officer
Executive Vice President and Chief Business Officer
Executive Vice President and Chief Business Officer
Published : 5 September 2019
By kalapian moi
Jozicular Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform,....
Published : 5 September 2019
By kalapian moi
Jozicular Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform,....
Published : 5 September 2019
By kalapian moi
Jozicular Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform,....
Collins Street West 8007,
San Fransico, United States.
Jozicular@gmail.com
Jozicular@gmail.com
+098 769 023
+098 769 024
Sign in with
google
